Advertisement
Advertisement
XLO
Xilio Therapeutics, Inc. Common Stock
9.04
USDSponsored
+0.02
+0.22%
Sep 22, 15:48 UTC -4
Closed
Pre-Market
9.09
+0.05
+0.50%
XLO Earnings Reports
Positive Surprise Ratio
XLO beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, XLO reported earnings of -0.33 USD per share (EPS) for Q2 26, beating the estimate of -0.59 USD, resulting in a 44.62% surprise. Revenue reached 18.69 million, compared to an expected 12.85 million, with a 45.49% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Xilio Therapeutics, Inc. Common Stock reported EPS of -$0.33, beating estimates by 44.62%, and revenue of $18.69M, 45.49% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- 0%, changed from $7.73 before the earnings release to $7.73 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.